Johnson & Johnson Q3 Results Prompt Mixed Analyst Reactions
Johnson & Johnson reported third-quarter sales of $25.4 billion and non-GAAP EPS of $2.59. The company raised its 2026 sales and non-GAAP EPS guidance, though analysts said parts of the outlook and product mix were disappointing.
Johnson & Johnson shares rose in early Wednesday trading after the company posted better-than-expected third-quarter results. RBC Capital Markets analyst Trung Huynh kept an Outperform rating but lowered his price target from $290 to $280. Guggenheim Securities analyst Vamil Divan reaffirmed a Buy rating. Huynh said the sell-off in Johnson & Johnson shares appeared “excessive” given that quarterly results were in line and the company raised its guidance.
” Results from the LIBREXIA-STROKE study are expected this year, while the LIBREXIA-AF trial remains on track for the first quarter of 2027, Huynh said. He added that Darzalex underperformed in the third quarter because of lower pricing outside the US, while sales volume remained strong. Huynh also noted that Johnson & Johnson expects 2027 sales growth to be similar to 2026 after adjusting for foreign currency headwinds, upcoming patent expirations (loss of exclusivity) and the impact from the extra week. 38 billion consensus estimate.
52 per share. 15 per share. 19, respectively, Divan said. Investors may be disappointed that some of the sales upside came from older products, including Stelara and Simponi.
Tremfya and Tecvayli were “the only newer and strategically important products that appear to have meaningfully beat expectations,” the analyst wrote. MedTech results, particularly in the Cardiovascular segment and at Abiomed, were also “somewhat disappointing,” he said. 60 at the time of publication on Wednesday.